Is Acerus Pharmaceuticals stock a buy?
What Is The Conclusion?
Right now our advanced algorithms say:
Do the analyst corps agree?
Interesting Questions and Easy Answers!
We cannot find any recorded dividends paid in our systems.
Sorry, we do not have any analyst data for this ticker
We cannot find data for Acerus Pharmaceuticals 10 years ago, but if you had invested on Thursday 6th of January 2022 when the price was $0.0260, you would have made a profit of $0.194 per share or 747.32%
No, the average daily trading liquidity for Acerus Pharmaceuticals is $69 thousand. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
Acerus Pharmaceuticals has N/A of the business financed by loans. This puts the company at N/A risk in periods of high inflation where borrowing costs usually go up. With a N/A cash flow to debt ratio of 0, the company's ability to pay off the debt is N/A. The company is still not profitable, and high inflation will make it harder to become profitable as costs increase and consumer spending decreases.
We have calculated the inflation risk for Acerus Pharmaceuticals to be low [0 of 1]
US inflation for August 2024 was 0.19%. Over the last 12 months, the US inflation is 2.59%. The 10-year treasury yield that indicates the future interest level is currently 4.41 and is up 0.05 over the last 30 days.